Demos include AI Processing of 100 simultaneous video streams, industrial defect detection, Yolo-World, and a comparison with NVIDIA GPUs ANN ARBOR, Mich., Dec. 19, 2024 /PRNewswire/ -- MemryX Inc., a leader in edge AI accelerators, will unveil cutting-edge demonstrations of the MX3 AI Accelerator during the 2025 Consumer Electronics Show (CES) in Las Vegas. Taking place at the Palazzo Hotel from Jan. 7–10, demos will highlight the MX3 industry leading performance, efficiency, and versatility in real-world Edge AI applications. Featured demos include: In Q4 2024, MemryX announced the availability of production MX3 modules and the public release of a . This, along with a recent offers an full ecosystem of tools and resources to simplify AI implementation and accelerate deployment timelines. "CES 2025 provides the first opportunity for us to showcase MemryX production quality hardware and software already in the hands of many customers," said Keith Kressin, CEO of MemryX. "We are excited to showcase our unique combination of efficiency, scalability, and ease of use that enables customers to quickly and efficiently deploy AI solutions." "ASUS has integrated the MemryX MX3 into our edge AI devices, and the results have been transformative," said Jessy Li AIoT Functional Director, Smart Manufacturing, ASUS. "The seamless integration and powerful performance of the MX3 have opened new possibilities for AI at the edge, delivering an exceptional experience for our customers." "Our collaboration with MemryX brings cutting-edge AI acceleration to industrial automation, as showcased in our Xi-MX3 system performing real-time quality inspections," said Ed Gatt, DYNICS President. "These types of integrated solutions not only streamline operational efficiency but also empower businesses to fully embrace the transformative potential of Industry 4.0, driving innovation, productivity, and a competitive edge in the evolving industrial landscape." MemryX's MX3 AI Accelerator is built to deliver unparalleled versatility and performance for edge AI applications. Key benefits include: Best-in-class performance-per-watt: Optimized for low power consumption without compromising on speed or accuracy. Broad compatibility: Supports popular AI frameworks (e.g., TensorFlow, ONNX, PyTorch), host processors (e.g., x86, Arm, RISC-V), and operating systems (e.g., Linux, Windows, Android). Scalability and reliability: Handles complex AI workloads with ease, from consumer electronics to industrial automation. MemryX invites CES attendees to experience the groundbreaking demos and connect with its leadership team. To schedule a meeting, email . Walk-ins are welcome at the MemryX suite at the Palazzo Hotel during CES. About MemryX MemryX Inc. is a fabless semiconductor company pioneering AI processing solutions for edge devices. Powered by proprietary compute-at-memory technology, MemryX accelerators combine high performance and low power to enable efficient, scalable AI for industries including IoT, transportation, and industrial automation. MemryX is backed by top investors and has headquarters in Ann Arbor, Michigan, with offices in Bangalore, India, and Taipei and Hsinchu, Taiwan. Visit . **Media Contact** Alan Frost Head of Corporate Marketing, MemryX Email: This updated release combines CEO and customer quotes to underscore MemryX's innovation and real-world impact. View original content to download multimedia: SOURCE MemryXA fresh strife has broken out between administration and faculty members of the Indian Institute of Technology, Kharagpur (IIT-KGP) following an order by university authorities to relocate staff and infrastructure from an on-campus medical facility to a newly established hospital at nearby Balrampur, allegedly without consultation with teachers, staff, officers or students. On Thursday, the IIT-KGP administration ordered the relocation of staff and infrastructure from Dr. B.C. Roy Technology Hospital (BCRTH) on campus to the new 400-bed Dr. Syama Prasad Mookerjee Superspeciality Hospital (SPMSH) in Balarampur, on the outskirts of IIT-KGP campus, as per directions of the Union Ministry of Education. SPMSH, a part of IIT-KGP, was inaugurated in March 2022. “Relocation work shall be completed within a time line as felt appropriate. Detail of relocation at micro level will be prepared & executed by the Medical Superintendent, SPMSH / Head, BCRTH in consultation with Project Director, SPMSH,” the order further read. However, the IIT Kharagpur Teachers’ Association (IITTA) has alleged that none of the recognised bodies representing teachers, staff, officers or students have been consulted prior to the order, despite the existence of a ‘Hospital Management Committee’ meant to represent all stakeholders. “As this is going to be a highly disruptive move, it needs a thorough discussion and, may be, it would be prudent to take advice from a larger cross-section of campus community and the students as well as the retired pensioners living outside the periphery of the campus,” the IIT-KGP teachers’ body wrote in a letter to the Chairperson of the Board of Governors of IIT-KGP today. In the letter, IITTA also raised questions as to why the shifting has been scheduled a week before the expiry of the tenure of the present Director. “In view of the fact that we are going to get a new incumbent Director from the 1st January, 2025, we wonder what is the big hurry to execute the proposed shifting on the 24th December, 2024, exactly a week before the expiry of the tenure of the present Director? Why cannot we all have a more thorough discussion with the next Director before such a big move is executed?” the teachers’ body asked in the letter. According to the order, the relocation is set to be completed by December 23. They also requested the Chairperson to keep the proposed order in abeyance and allow the future incoming Director to do the needful in this regard. An anonymous source at the IIT-KGP told The Hindu that the 400-bed hospital is not the primary healthcare facility on campus yet. “It is a misuse of resources given that the SPMSH is barely functional yet,” the source said, and highlighted that meanwhile, according to the order, only emergency primary care and the pharmacy will continue to remain functional at BCRTH. “IITTA objected to this move very strongly because this will be extremely inconvenient for students, faculties and all other campus community,” the source said. This development acquires significance in light of 86 professors being issued show-cause notices and disciplinary action by the Institute administration on November 12, after the IITTA wrote to the Union Ministry of Education alleging unfair and arbitrary hiring practices in the Institute. The show cause notice issued by the Registrar of IIT Kharagpur read, “Failure to provide a satisfactory explanation or response within the stipulated time may lead to... disciplinary action.” However, disciplinary cases against some of the faculty members were recently withdrawn after they issued apologies. Published - December 13, 2024 11:59 pm IST Copy link Email Facebook Twitter Telegram LinkedIn WhatsApp Reddit West Bengal / educationFLORHAM PARK, N.J. (AP) — New York Jets running back Breece Hall could play Sunday at Jacksonville after missing a game with a knee injury. Hall has been dealing with a hyperextension and injured MCL in his left knee that sidelined him last Sunday at Miami. But he was a full participant at practice Friday after sitting out Wednesday and Thursday. Hall was officially listed as questionable on the team's final injury report. “He looks good right now,” interim coach Jeff Ulbrich said. “So it’s promising.” Hall leads the Jets with 692 yards rushing and four touchdown runs, and he also has 401 yards receiving and two scores on 46 catches. A pair of rookies helped New York offset Hall's absence last weekend, with Braelon Allen rushing for 43 yards on 11 carries, and Isaiah Davis getting 40 yards on 10 attempts and scoring his first rushing touchdown. “We’re hopeful and we’ll see how it goes,” Ulbrich said of Hall. The Jets will get star cornerback Sauce Gardner back after he missed a game with a hamstring injury, but New York's secondary appears likely to be without cornerback D.J. Reed because of a groin injury. Reed was listed as doubtful after he didn't practice Thursday or Friday. “It’s been something that’s kind of lingered here and there,” Ulbrich said. “It’s gotten aggravated and then it went away, and then it got aggravated again. So, it’s just dealing with that.” Story continues below video Backup Brandin Echols is out with a shoulder injury, so veteran Isaiah Oliver or rookie Qwan'tez Stiggers could get the start opposite Gardner if Reed can't play. Kendall Sheffield also could be elevated from the practice squad for the second game in a row. Ulbrich said kick returner Kene Nwangwu will be placed on injured reserve after breaking a hand last weekend at Miami. The injury came a week after he was selected the AFC special teams player of the week in his Jets debut, during which he returned a kickoff 99 yards for a touchdown and forced a fumble in a loss to Seattle. “To put him out there with a broken hand, just thought it’d be counterproductive for him and for us as a team, so it unfortunately cuts the season short and what a bright light he was,” Ulbrich said. “What an amazing future I think he has in this league. With saying that, he’s already been a really good player for quite a while, so (it's) unfortunate, but he’ll be back.” Offensive lineman Xavier Newman (groin) is doubtful, while right guard Alijah Vera-Tucker (ankle) and RT Morgan Moses (wrist) are questionable. AP NFL: https://apnews.com/hub/NFL
If you need a screen to go with the upgrade that you made with desktop computer deals , and you’re willing to spend for a top-of-the-line display, then you may want to set your sights on the LG 40WP95C-W UltraWide curved 5K monitor. From its original price of $1,800, you can get it for $1,240 from Walmart for huge savings of $560, or for $1,275 from Amazon for a $525 discount. You should complete your purchase quickly if you’re interested though, as there’s no telling when the offers for this monitor will expire. Why you should buy the LG 40WP95C-W UltraWide curved 5K monitor 5K monitors are highly recommended for serious creative professionals, such as graphic designers and filmmakers, for their extremely sharp details and precise colors, and the LG 40WP95C-W UltraWide curved 5K monitor is an excellent choice. We’ve tagged it as the best ultrawide 5K monitor in our roundup of the best 5K monitors , with its huge 40-inch curved screen featuring 5120 x 2160 resolution, 98% coverage of the DCI-P3 spectrum, and support for HDR10 providing striking visuals that you won’t enjoy from most of the other options in the market. The LG 40WP95C-W UltraWide curved 5K monitor works with Thunderbolt 4 for faster bandwidth, alongside a DisplayPort, two HDMI ports, a 3.5mm audio jack, and two USB 3.0 Type-A ports. You can use it for gaming as it’s equipped with AMD’s FreeSync technology that eliminates screen tearing and stuttering, and it also comes with built-in 10W speakers if you prefer not to use headphones or external speakers. The LG 40WP95C-W UltraWide curved 5K monitor also has a low blue light filter mode and auto-brightness with ambient light sensor, to keep your eyes comfortable while you look at its screen. While some monitor deals offer affordable screens at even lower prices, you can also enjoy huge savings on premium models like the LG 40WP95C-W UltraWide curved 5K monitor. Originally sold for $1,800, Walmart is offering a $560 discount that brings it down to $1,240, but it’s also available from Amazon for $1,275 for $525 in savings. No matter where you decide to buy the LG 40WP95C-W UltraWide curved 5K monitor, you need to act fast because these bargains may end at any moment, and once they’re gone, we’re not sure when you’ll get another chance at them.Donald Trump’s reelection could bring new energy to a Washington state fight for abortion access begun in the courts last year. Earlier this month, Bob Ferguson — then attorney general, now governor-elect — filed a summary judgment motion requesting that an ongoing case challenging restrictions on the common abortion drug mifepristone be decided without a trial. If the judge sides with Ferguson, the Food and Drug Administration could be obligated to revisit their policies on the drug used in more than half of all abortions. According to Brionna Aho, a spokesperson with the Attorney General’s Office, the FDA’s response is expected Dec. 6. “We are continuing to fight for reproductive freedom, including access to mifepristone,” said Ferguson in a news release announcing the motion. “The FDA must remove its unnecessary and unlawful restrictions on this safe and effective medication.” In a joint lawsuit with 18 other attorneys general filed last year in the U.S. District Court for the Eastern District of Washington in Spokane, Ferguson and his staff argued that restrictions on mifepristone are illegal, and that the FDA should reevaluate its policies on the drug. In April 2023, Judge Thomas O. Rice approved a preliminary injunction requested by Ferguson that prevents the FDA from interfering with the availability of mifepristone in Washington, Oregon, the District of Columbia, and 16 other states that have signed on to the lawsuit. Rice’s ruling last year was released the same day another decision on mifepristone came out in a Texas lawsuit, in favor of anti-abortion advocates who argued that the already unusually restrictive rules around mifepristone were inadequate. That ruling, which would’ve rescinded FDA approval for the drug, made its way to the U.S. Supreme Court, where, in June, the Court disagreed, deciding unanimously that the anti-abortion advocates who brought the suit in Texas lacked a legal right to sue . While that case was rejected, abortion challenges are not likely over. Trump has bragged publicly about the reversal of Roe v. Wade enabled by the Supreme Court picks he made during his first presidency, while abortion was an issue in both federal and state elections this year. Mifepristone is limited under what’s known as a Risk Evaluation & Mitigation Strategy, a set of regulations the FDA requires for just 73 drugs, including those with well-established addictive properties or that are known to cause birth defects, for example opioids, thalidomide, and isotretinoin . Mifepristone is also restricted under a policy called Elements to Assure Safe Use, which is typically applied to drugs that carry high risk. For years, abortion rights advocates and providers have argued that the restrictions on mifepristone are scientifically baseless and burdensome, pointing out that there are no similar requirements when mifepristone is prescribed for purposes aside from pregnancy termination. Mifepristone is also commonly used to manage high blood sugar in patients with Cushing syndrome. “There is, truly, zero science or medicine to support it,” said Sarah Prager, a Seattle-area abortion provider and professor of obstetrics and gynecology at the University of Washington. According to Prager, recent changes in how mifepristone is prescribed have made it even more challenging to provide it to patients. “Each individual provider now needs to be registered with each pharmacy that will dispense the medication for them,” she said. “Additionally, mifepristone is a medication safer than many over-the-counter medications and should not have ANY restrictions in use.” The Washington Attorney General’s Office agrees, saying that “The stigma and administrative burdens associated with becoming ‘specially certified’ to prescribe and dispense an abortion medication deters many health care providers and pharmacies from signing up to do so in the first place.” But without the FDA rules, “any qualified health care provider would be able to prescribe mifepristone — just as they can for any other prescription drug, including high-risk drugs such as opioids.” Oregon Attorney General Ellen Rosenblum, who is co-leading the lawsuit with Ferguson, agrees: “The restrictions simply are not medically necessary.” In medication abortions, mifepristone is typically paired with a second drug, misoprostol, to end a pregnancy. The same FDA rules do not apply to misoprostol, which can also be used on its own to end a pregnancy , a protocol reproductive health care providers have indicated they would pivot to if mifepristone is further restricted. Beyond broader questions of access, the Attorney General’s Office is also concerned that current restrictions on mifepristone could introduce privacy concerns for patients, especially for those seeking care in Washington from states with abortion-hostile policies enacted since Dobbs v. Jackson Women’s Health was decided more than two years ago. That’s because the restrictions on mifepristone currently include written agreements stating that the drug is being used to induce an abortion or resolve a miscarriage, evidence that could leave patients vulnerable to investigation or prosecution by abortion-hostile state officials.
While CarMax reported solid third-quarter results Thursday (Dec. 19), including a 5.4% increase in retail used unit sales and a 6.3% rise in wholesale unit sales, company officials attributed this growth to strong execution across its business model, led by its omnichannel strategy. This strategy has become a key differentiator, according to CEO Bill Nash . CarMax uses advanced technology to improve car images, reviews and details, providing targeted content based on individual customer preferences. It also aggregates information into easily digestible summaries, making the car-buying process more efficient for customers. “Omnichannel capabilities have strengthened our business model,” Nash shared with analysts during the earnings call . “We’re focused on refining the experience for associates and customers. We want to make the experience better with less friction and more conversion. I’m not sure the consumer’s mindset has changed. It’s more driven by things we’re doing. We’re focused on removing that friction. Consumers are going to want this type of experience and the more you can have it seamless and frictionless, that’s who’s going to win.” Streamlining the Buying Experience CarMax’s recent initiatives are focused on creating a more seamless car-buying experience, catering to the growing preference among consumers to blend online and in-store shopping, Nash noted, including the introduction of digital tools that allow customers to begin their journey online and smoothly transition to physical locations as needed. CarMax officials want to make sure customers receive consistent and efficient service, regardless of whether they start their purchase online or in-store. One of the key elements of CarMax’s strategy is how it has reduced friction for both customers and employees, Nash said. Automated assistants help customers complete digital steps in the car-buying process, a trend that has significantly improved conversion rates across its channels. While web traffic has remained largely stable, CarMax has seen positive momentum driven by higher levels of customer engagement, both online and in-store. “Our remote customers are more engaged, and we have more engaged customers in the store,” Nash said. “As prices have come down, that’s a tailwind for us. But equally important is the focus internally on execution of experiences and efficiencies. It’s because we’ve improved the experience.” Chief Financial Officer Enrique Mayor-Mora noted that web chats increased 10% during the quarter. “Consumers are doing more activities on their own,” Mayor-Mora said. “We’re fine-tuning that model. What that means is less labor but more effective labor. We’re really excited about that.” By the Numbers CarMax’s omnichannel experience push is reflected in the company’s third-quarter results. Online retail sales accounted for 15% of retail unit sales, a slight but notable increase from last year, and revenue from online transactions reached $2 billion, representing approximately 32% of net revenue. CarMax’s Auto Finance division also showed a strong performance, with a 7.6% increase in income, driven by higher net interest margins and managed receivables. “I am pleased with the positive momentum that we are driving across our diversified business model,” Nash said. “Our solid execution and a more stable environment for vehicle valuations enabled us to deliver robust EPS growth driven by increases in unit sales and buys, solid margins, growth in CAF income and ongoing management of SG&A. Our associates and our best-in-class omnichannel experiences are key differentiators that enable our success. We are excited to leverage the capabilities we have built to drive growth as we access the largest total addressable market within our industry.”New spiking offence aims to bring law up to date, minister says
Christopher Nolan is following his Oscar-winning “Oppenheimer” with a true epic: Homer’s “The Odyssey.” It will open in theaters on July 17, 2026, Universal Pictures said Monday. Details remain scarce, but the studio teased that it will be a “mythic action epic shot across the world using brand new IMAX technology.” It will also be the first time that an adaptation of Homer’s saga will play on IMAX film screens. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.Final regular-season games loom large in determining conference championship matchups
CARLSBAD, Calif. , Dec. 19, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZATM (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, genetic form of severe hypertriglyceridemia (sHTG) that can lead to potentially life-threatening acute pancreatitis (AP). TRYNGOLZA is the first-ever FDA-approved treatment that significantly and substantially reduces triglyceride levels in adults with FCS and provides clinically meaningful reduction in AP events when used with an appropriate diet (≤20 grams of fat per day). TRYNGOLZA is self-administered via an auto-injector once monthly. Experience the full interactive Multichannel News Release here: https://www.multivu.com/ionis-pharmaceuticals/9295551-en-tryngolza-olezarsen-fda-approval "Today's FDA approval of TRYNGOLZA heralds the arrival of the first-ever FCS treatment in the U.S. – a transformational moment for patients and their families. For the first time, adults with FCS can now access a treatment that substantially reduces triglycerides and the risk of debilitating and potentially life-threatening acute pancreatitis," said Brett P. Monia , Ph.D., chief executive officer, Ionis. "We are proud of our long-standing partnership with the FCS community and are grateful to the patients, families and investigators who participated in our clinical studies, enabling Ionis to make this new treatment a reality. The FDA approval of TRYNGOLZA is also a pivotal moment for Ionis, representing our evolution into a fully integrated commercial-stage biotechnology company – a goal we set out to achieve five years ago. With our rich pipeline of potentially life-changing medicines, we expect TRYNGOLZA to be the first in a steady cadence of innovative medicines we will deliver independently to people living with serious diseases." The FDA approval was based on positive data from the global, multicenter, randomized, placebo-controlled, double-blind Phase 3 Balance clinical trial in adult patients with genetically identified FCS and fasting triglyceride levels ≥880 mg/dL. In the Balance study, TRYNGOLZA 80 mg demonstrated a statistically significant placebo-adjusted mean reduction in triglyceride levels of 42.5% from baseline to six months (p=0.0084). Reductions from baseline to 12 months were further improved, with TRYNGOLZA achieving a placebo-adjusted 57% mean reduction in triglycerides. TRYNGOLZA also demonstrated a substantial, clinically meaningful reduction in AP events over 12 months; one patient (5%) experienced one episode of AP in the TRYNGOLZA group compared with seven patients (30%) who experienced 11 total episodes of AP in the placebo group. TRYNGOLZA demonstrated a favorable safety profile. The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and at a >3% higher frequency than placebo) were injection site reactions (19% and 9%, respectively), decreased platelet count (12% and 4%, respectively) and arthralgia (9% and 0%, respectively). Results from the Phase 3 Balance study were previously published in The New England Journal of Medicine (NEJM). "With no treatment options previously available, we were limited to relying only on extremely strict diet and lifestyle changes as the sole preventative treatment option," said Alan Brown , M.D., FNLA, FACC, FAHA, clinical professor of medicine, Rosalind Franklin University of Medicine and Science ; Balance trial investigator. "The FDA approval of TRYNGOLZA is an important moment for people living with FCS, their families and physicians who now, for the first time, have a treatment that significantly lowers triglycerides and decreases the risk of potentially life-threatening acute pancreatitis events, as an adjunct to a low-fat diet. I am excited to have a medicine I can prescribe to my patients that has been shown to change the course of their disease." FCS is a rare, genetic, potentially life-threatening form of sHTG that prevents the body from breaking down fats and severely impairs the body's ability to remove triglycerides from the bloodstream due to an impaired function of the enzyme lipoprotein lipase (LPL). While healthy levels for adults are below 150 mg/dL, people with FCS often have triglyceride levels of more than 880 mg/dL and often have a history of pancreatitis. Those living with FCS have a high risk of potentially fatal AP, which is a painful inflammation of the pancreas, and chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS can also experience psychological and financial stress, which can significantly impact their quality of life. In the U.S., FCS is estimated to impact up to approximately 3,000 people, the vast majority of whom remain undiagnosed. "As a rare and difficult to diagnose disease, FCS has a profound impact on the lives of patients and families. Many people living with FCS have experienced severe pain their whole lives – sometimes so intense they require lengthy hospitalization stays – and struggle through life with daily fatigue, nausea, brain fog and stomach pain," said Lindsey Sutton Bryan , co-founder and co-president, FCS Foundation. "Until now, our treatment options have been limited, relying on diet alone to try to manage triglyceride levels and keep acute pancreatitis attacks at bay. For the first time, adults with FCS have seen their hope for a treatment become a reality." TRYNGOLZA will be available in the U.S. before year end. Ionis is committed to helping people access the medicines they are prescribed and will offer a suite of services designed to meet the unique needs of the FCS community through Ionis Every StepTM. As part of Ionis Every Step , patients and healthcare providers will have access to services throughout the treatment journey provided by dedicated Patient Education Managers and Ionis Every Step Case Managers, including insurance and affordability support, as well as services and resources, such as disease and nutrition education. Visit TRYNGOLZA.com for more information. TRYNGOLZA was reviewed by the FDA under Priority Review and had previously been granted Fast Track designation for the treatment of FCS, Orphan Drug designation and Breakthrough Therapy designation. Olezarsen is undergoing review in the European Union and regulatory filings in other countries are planned. Olezarsen is currently being evaluated in three Phase 3 clinical trials – CORE, CORE2 and ESSENCE – for the treatment of sHTG. Olezarsen has not been reviewed or approved for the treatment of sHTG by regulatory authorities. Webcast Ionis will hold a webcast today at 6:45pm ET to discuss the FDA approval. Interested parties may access the webcast here . A webcast replay will be available for a limited time. About TRYNGOLZATM (olezarsen) TRYNGOLZATM (olezarsen) was approved by the U.S. Food and Drug Administration as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). TRYNGOLZA is an RNA-targeted medicine designed to lower the body's production of apoC-III, a protein produced in the liver that is a key regulator of triglyceride metabolism. It is the only treatment currently indicated in the U.S. for FCS, a potentially life-threatening disease. For more information about TRYNGOLZA, visit TRYNGOLZA.com . IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS TRYNGOLZA is contraindicated in patients with a history of serious hypersensitivity to TRYNGOLZA or any of the excipients in TRYNGOLZA. Hypersensitivity reactions requiring medical treatment have occurred. WARNINGS AND PRECAUTIONS Hypersensitivity Reactions Hypersensitivity reactions (including symptoms of bronchospasm, diffuse erythema, facial swelling, urticaria, chills and myalgias) have been reported in patients treated with TRYNGOLZA. Advise patients on the signs and symptoms of hypersensitivity reactions and instruct patients to promptly seek medical attention and discontinue use of TRYNGOLZA if hypersensitivity reactions occur. ADVERSE REACTIONS The most common adverse reactions (incidence >5% of TRYNGOLZA-treated patients and >3% higher frequency than placebo) were injection site reactions, decreased platelet count and arthralgia. Please see full Prescribing Information for TRYNGOLZA. About Familial Chylomicronemia Syndrome (FCS) FCS is a rare, genetic disease characterized by extremely elevated triglyceride levels. It is caused by impaired function of the enzyme lipoprotein lipase (LPL). Because of limited LPL production or function, people with FCS cannot effectively break down chylomicrons, lipoprotein particles that are 90% triglycerides. FCS is estimated to impact up to approximately 3,000 people in the U.S. People living with FCS are at high risk of acute pancreatitis (AP) in addition to other chronic health issues such as fatigue and severe, recurrent abdominal pain. People living with FCS are sometimes unable to work, adding to the burden of disease. About the Balance Study Balance is a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of olezarsen in patients with FCS at six and 12 months. The primary endpoint was the percent change from baseline in fasting triglyceride levels at six months compared to placebo. Secondary endpoints included percent changes in triglyceride levels at 12 months, percent changes in other lipid parameters and adjudicated acute pancreatitis event rates over the treatment period. Following treatment and the end-of-trial assessments, patients were eligible to enter an open-label extension study to continue receiving olezarsen once every four weeks. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis has discovered and developed six marketed medicines for serious diseases, including breakthrough medicines for neurologic and cardiovascular diseases. Ionis has a leading pipeline in neurology, cardiology and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter) , LinkedIn and Instagram . Ionis Forward-Looking Statements This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of TRYNGOLZA, Ionis' technologies and other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including but not limited to those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended Dec. 31, 2023 , and most recent Form 10-Q, which are on file with the SEC. Copies of these and other documents are available at www.Ionis.com . Ionis Pharmaceuticals® and TRYNGOLZATM are trademarks of Ionis Pharmaceuticals, Inc. Ionis Investor Contact: D. Wade Walke , Ph.D. info@ionis.com 760-603-2331 Ionis Media Contact: Hayley Soffer media@ionis.com 760-603-4679 View original content: https://www.prnewswire.com/news-releases/tryngolza-olezarsen-approved-in-us-as-first-ever-treatment-for-adults-living-with-familial-chylomicronemia-syndrome-as-an-adjunct-to-diet-302336747.html SOURCE Ionis Pharmaceuticals, Inc.Christopher Nolan’s next film is based on ‘The Odyssey’Light-Induced Gene Therapy Disables Cancer Cells’ Mitochondria in Mice
Share Tweet Share Share Email December 19, 2024 – Roam, the leader of decentralized global open wireless network, announced a major milestone today: the Roam Network has surpassed 1 million active WiFi nodes , supported by over 1.7 million registered users across 190+ countries and regions . This achievement highlights Roam’s continued success in delivering innovative solutions to create a free,secure and seamless network . At its inception in 2021, Roam identified the challenges faced by the Wireless Broadband Alliance (WBA) in scaling OpenRoamingTM globally. By integrating Web3 technologies , including Decentralized Identifiers (DID) and Verifiable Credentials (VC) , Roam has fostered community-driven growth and secured its position as a pioneer in the DePIN (Decentralized Physical Infrastructure Network) sector. 2025 Roadmap: Accelerating Innovation Across Products, Technology, and Ecosystem Roam also unveiled its ambitious 2025 roadmap , outlining 11 key updates spanning product ,technology and community ecosystem growth. Product Updates Roam will roll out four major product launches: Q1: Roam Loan – A groundbreaking initiative in partnership with Huma Finance , enabling users to acquire mining hardware with low/none upfront costs. Payments are seamlessly deducted from mining rewards, ensuring a user-friendly “Buy Now, Pay Later” experience. Q2: Roam Growth – Enhancements to the Roam Growth platform, introducing a sustainable framework to maximize user rewards and upgrade the existing product suite. Q3: Roam App 2.0 – A revamped app delivering a richer, more interactive user experience with expanded connectivity features. Q4: Roam Innovator Hub – A comprehensive platform offering APIs , SDKs , and grants to empower developers to build and innovate within the Roam ecosystem. Technological Advancements Roam’s technology roadmap emphasizes seamless integration and performance: Proof of Presence Protocol (Q1) – Real-time validation and verification of local interactions within the Roam Network. Router OS Updates & Next-Gen WiFi Miners (Q3) – Launch of new WiFi mining devices, including third-party certified hardware and OpenRoamingTM-enabled community devices. Fully Converged Wireless Network (Q4) – Integration of WiFi and cellular data networks to enable seamless, uninterrupted global roaming. Community Ecosystem Expansion To strengthen its global user base, Roam will introduce: Roam eSIM Long-Term Plan (Q1) – An industry-first eSIM offering with no expiration, no binding commitments, and no monthly fees, providing ultimate convenience for users worldwide. Roam Discovery Program (H1) – A suite of initiatives, including Discovery Pool , Discovery IMPACT , and the Discovery Incubator , designed to attract industry leaders, investors, and innovators. Community DAO Governance (H2) – A decentralized governance framework that empowers users to participate actively in shaping the Roam Network’s future. A Year of Strategic Growth and Recognition Roam’s commitment to steady, incremental progress has driven its exceptional growth. In 2023, Roam secured $5 million in strategic funding , led by Anagram and Volt Capital , with participation from Comma3 Ventures , ECMC Group , and continued support from early investors Synergis and SNZ . In April 2024 Samsung Next made a notable investment in Roam, which also made it the only investment from Samsung Next in this sector since DePIN had been defined by Messari. This year, Roam’s hardware node count maintained its leadership position on DePINscan , and the network’s expansion to over 1 million nodes underscores its effectiveness in bridging Web3 innovation with real-world connectivity solutions. Building the Future of Global Connectivity As Roam looks ahead to 2025, the team remains steadfast in its mission to provide secure, seamless, and accessible global connectivity. With a user base spanning over 190 countries, Roam continues to transform WiFi and cellular networks, empowering communities and developers to create sustainable digital economies. Roam’s journey from 0 to 1 million nodes reflects their commitment to building a truly decentralized global network. The 2025 Roadmap marks the next phase of growth, delivering cutting-edge products, breakthrough technologies, and a thriving ecosystem to meet the evolving needs of the users worldwide. About Roam Roam is a DePIN open wireless network engaging OpenRoaming & eSIM technologies to create a free, secure & seamless decentralized global network . With over 1.7 million users in 190+ countries, Roam is dedicated to creating innovative products and tools that empower communities, developers, and the ecosystem. Related Items: decentralized global network , Roam Share Tweet Share Share Email Recommended for you Roam Ranks #1 on DePINscan, Paving the Way for DePIN’s Future Roam Revolutionizes Travel Connectivity: A Milestone of 1 Million Users Roam Telecom Data Layer: A Revolutionary Ecosystem Uniting People, Devices, and Data CommentsUTSA earns 117-58 win against Southwestern Adventist
Ancient meets modern as a new subway in Greece showcases archaeological treasuresJaland Lowe, Pitt charge past LSU in second half to move to 6-0
WASHINGTON — The Department of Homeland Security is investigating Chinese online retailer Temu for possible violations of the Uyghur Forced Labor Prevention Act, which could lead to a ban from selling their wares in the US, The Post has exclusively learned. Officials and intelligence experts tell The Post that the too-cheap-to-beat company plays an unfair role in the US market, spies on its mobile app users and relies on products made from slave labor to get its dirt-cheap pricing. A senior DHS official confirmed to The Post that the agency has been investigating Temu for slave-labor violations, but the Biden administration has yet to take action against the retailer. It was noticeably absent from a list of 29 Chinese companies added Friday to the US’ banned list for violating the UFPLA. Drafted and advanced under the Trump administration and signed into law by President Biden in 2021, the UFLPA outlaws the import of goods “manufactured wholly or in part with forced labor” in China, especially from Xinjiang — home to Uyghur Muslims that China has placed in forced-labor camps. Companies found to have violated that provision are placed on the UFPLA entity list and barred from selling any products in the US. “[Customs and Border Protection]’s enforcement of this act is crucial to ensuring that goods entering the US are not the product of human suffering,” the agency has said. The law is one of the most forceful US responses to Beijing’s “systemic use of forced labor against Uyghurs and other ethnic minorities in the Xinjiang Uyghur Autonomous Region,” according to CBP. Launched in 2022, Temu has flooded the US and European markets with products ranging from clothing to keychains to furniture — at just a fraction of the cost. The website’s bestseller on Monday, a “luxurious faux rabbit fur throw blanket,” was listed on Temu for $12.05 — less than a third of what the same product sells for on Amazon. Kevin Hulbert, a former senior intelligence officer in the CIA’s Directorate of Operations and CEO of XK Group Business Intelligence, told The Post that Temu’s suspiciously low prices have alarmed officials for years. “It’s just incredible that those guys can make a dress, ship it halfway around the world and sell it for, you know, $8 or something, and so those put all sorts of US businesses out of business,” Hulbert said. “And then comes in a question of how do they do that?” “They do it probably by having really cheap cotton in their goods and stuff, and so that’s an issue. We shockingly allow Temu to self-certify that none of their cotton comes from the Xinjiang province, which is where slave labor’s used.” With a new presidential administration on the horizon, some national security hawks are calling on the US to take away Temu’s ability to “self-certify” that their company does not violate the UFLPA. There are advanced technologies in the intelligence sphere to prove or disprove their reliance on Xinjiang-sourced goods by testing the origin of some products, such as cloth, Hulbert said. However, it’s unclear whether DHS has used the method on items from Temu. “You can forensically test cotton and see where it’s from,” he noted. “If you’re wearing a cotton T-shirt right now, for example, I could take that cotton T-shirt off you, and I could test it forensically and tell you if that cotton was produced, grown and produced in Mississippi, Alabama, or if it was from Tajikistan, or if it was from China — or if it was specifically from the Xinjiang province in China.” “So that capability’s out there,” he added. The House Select Committee on the Chinese Communist Party in June 2023 called on the federal government to investigate the CCP-linked company in a report that alleged Temu’s business model allows the company to avoid responsibility in complying with the UFPLA unless businesses can prove the items were made without forced labor. “American consumers should know that there is an extremely high risk that Temu’s supply chains are contaminated with forced labor,” the report said. There are also cyber security risks with users of Temu’s mobile app that raise similar concerns to that which lead to Congress’ ban on the social media platform, TikTok, which was accused of spying on its users and allowing Beijing access to the data. A senior DHS official told The Post “there’s no way I would download that to my phone.” It’s unclear whether those allegations are under investigation by the agency. The European Union last month launched a probe into Temu, including whether the company violated its Digital Services Act with practices “linked to the sale of illegal products, the potentially addictive design of the service, the systems used to recommend purchases to users, as well as data access for researchers.” Reps for Temu did not immediately respond to a request for comment.FLORHAM PARK, N.J. (AP) — New York Jets running back Breece Hall could play Sunday at Jacksonville after missing a game with a knee injury. Hall has been dealing with a hyperextension and injured MCL in his left knee that sidelined him last Sunday at Miami. But he was a full participant at practice Friday after sitting out Wednesday and Thursday. Hall was officially listed as questionable on the team's final injury report. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.
The other day, the duo met at a ‘power dinner’ in New Delhi. Both gentlemen have graced the Union Cabinet of ministers as members of opposing coalitions. They fielded identical questions: What would be the outcome of the Maharashtra polls? I humbly fielded a counter question: Please enlighten me, as both of you are the quintessential political insiders. The member of the ruling dispensation asserted that his coalition would return to power, insisting that he was convinced that Prime Minister (PM) Narendra Modi possesses a siddhi (magic wand) that helps him wriggle out of the tightest of situations. This election will be another testimony to that “magic”. The opposition leader, on the other hand, threw up his hands in exasperation and said: “I have given up election forecasts after the Haryana results. I don’t know what ‘secret sauce’ the Bharatiya Janata Party (BJP) uses to cast a spell on the electorate in the last few days of the campaign and all our calculations go for a toss.” Incidentally, he had returned from Mumbai the same day after attending a marathon election campaign review. Pay attention to the words of the two veterans — siddhi and secret sauce. What does it mean? The member of the ruling coalition wasn’t talking about PM Modi’s special spiritual powers, instead, he was referring to his brilliant political skills and uncanny ability to read people’s minds. That’s the reason the BJP workers believe even if the party’s seats diminish in any election, it will more than make up in the next. This belief not only fills them with confidence but inspires them to soldier on as a tight-knit unit. The election results in Maharashtra and Uttar Pradesh have proved that the ghosts of setbacks in the general election have been laid to rest. The BJP suffered an electoral humiliation in both the states just a few months ago. The Opposition leader’s statement betrays the fact that the Congress-led INDIA bloc is facing a crisis of confidence to secure an electoral victory. The Maharashtra victory wasn’t scripted easily. The task was tough and the challenges were many. Ever since Eknath Shinde and Ajit Pawar severed the umbilical cords from their parent organisations to chart their own course, experts thought the public would punish these villains for their betrayal. Uddhav Thackeray and Sharad Pawar tried to milk the element of sympathy but failed miserably. The reason was the Mahayuti government was able to successfully stall the Maratha consolidation which led to their poor showing in the general election. Similarly, Ajit Pawar, was encouraged to win over the Muslim votes. This proved to be the death knell for Maha Vikas Agadhi (MVA). The Ladki Bahin scheme introduced four months before the assembly elections proved to be the game-changer as it hit the right chord with women voters. The women are continually increasing their electoral clout with each passing election. In Jharkhand, they threw their weight behind Hemant Soren. Even Soren made inroads in half of the electorate with the Maiya Samman (mother’s pride) scheme. These elections have made it clear that sympathy and legacy aren’t enough to ensure victory. You need to work on the ground. In Maharashtra, the BJP didn’t make any mistakes. The tricky task of ticket distribution and coalition partner management was handled with care and a lot of wisdom under the leadership of Union home minister Amit Shah. And the results speak for themselves. The BJP with a strike rate of 88.6%, Shinde’s Shiv Sena with 71.3%, and Ajit Pawar’s Nationalist Congress Party’s 69.5% have all contributed to the landslide victory. Now that the results are out, the names of Shinde, Devendra Fadnavis, and Ajit Pawar may pop up as possible chief minister (CM) candidates. During the election campaign, they desisted from making any loose comments. On the contrary, the MVA leaders were all over the place making contradictory statements. So, why did the BJP juggernaut fail in Jharkhand? There are many reasons. Unlike in Maharashtra, there weren’t heavy-weight leaders in the NDA in Jharkhand. In the INDIA bloc, there was no one to challenge Hemant Soren’s stature. So, there was no confusion in the rank and file as well as among the voters. His arrest, a few months before elections, subsumed anti-incumbency. The BJP did attempt a Maharashtra-like defection but Champai Soren couldn’t repeat the feats of Eknath Shinde or Ajit Pawar. Another trend that became visible in these elections is the Congress Party is steadily losing its ability to win in the Hindi heartland on its own. It can help Soren, Tejaswi Yadav, or Akhilesh Yadav win but in the bargain, it’s losing its vote base. Even after the setback in Jharkhand, it is clear that the BJP will prepare for the coming elections with renewed gusto. Another benefit will be that the NDA partners will work with the PM with greater deference. It will help PM Modi expedite his agenda and schemes. We can also hazard a guess as to what will happen to Eknath Shinde. He has held his own against Uddhav Thackeray, but he still has to emerge as Balasaheb Thackeray’s natural heir. If he’s unable to retain the CM’s post, he may have to face new challenges in the future. As far as the Opposition is concerned, it can brush off the drubbing, insisting that it has won two out of four states that have held assembly elections since June. Priyanka Gandhi has won her election from Wayanad. Will she be able to provide a fresh lease of life in the Congress along with her brother Rahul Gandhi? It’s clear the Opposition has received a big jolt, yet they have enough room to rest and recuperate. This is the beauty of Indian democracy. There’s always space for everyone. Shashi Shekhar is editor-in-chief, Hindustan. The views expressed are personalLana Del Rey has announced the release date for her next album, , . With 13 tracks featuring production from Jack Antonoff, Drew Erickson, and Luke Roberts, the album is due on May 21, 2025. Lana also plans to release some songs ahead of her headlining performance at next year’s , starting with one called “Henry.” The announcement comes a month after that “I don’t want to turn it into something that’s half cooked.” She also promised a strong Americana influence in an , noting, “The music business is going country. That’s why Jack [Antonoff] has followed me to Muscle Shoals, Nashville, Mississippi, over the last four years.” However, she also denied that it’d be a huge departure for her, saying, “All my albums are somewhat rooted in Americana, unless it’s an album like which has a jazz flair, so I don’t think it will be a heavy departure.” While fans waited on tenterhooks for news of her next release, it appears that Del Rey went out and . In September, she reportedly got , saying that they’re “very happy.” is due on 5/21/25 via Interscope and Polydor.
NEW YORK (AP) — A man accused of setting a woman on fire inside a New York City subway train and then watching her die after she was engulfed in flames made an initial court appearance Tuesday and will remain in custody. Sebastian Zapeta, 33, who federal immigration officials said is a Guatemalan citizen who entered the U.S. illegally, was arraigned in Brooklyn criminal court. He appeared briefly before a judge and wore a white jumpsuit over a weathered black hooded sweatshirt. He did not speak. He will remain jailed ahead of his next court date on Friday. The apparently random attack occurred Sunday morning on a stationary F train at the Coney Island station in Brooklyn. Police said Tuesday that identification of the victim was still “pending at this time.” Authorities say Zapeta approached the woman, who was sitting motionless in the train car and may have been sleeping, and used a lighter to set her clothing on fire. The woman quickly became engulfed in flames, while the suspect then sat at a bench on the subway platform and watched, according to police. Video posted to social media appeared to show the woman standing inside the train ablaze as some people look on from the platform, and at least one officer walks by. NYPD Chief of Transit Joseph Gulotta said Sunday that several officers had responded to the fire and one stayed to keep the crime scene “the way it’s supposed to be" while the others went to get fire extinguishers and transit workers. They were eventually able to douse the fire, but “unfortunately, it was too late,” Police Commissioner Jessica Tisch said — the woman was pronounced dead at the scene. During Zapeta's court hearing on Tuesday, Assistant District Attorney Ari Rottenberg said Zapeta at one point fanned the flames on the woman using his shirt. He said a 911 call from a subway rider helped identify Zapeta. Rottenberg added that under interrogation Zapeta claimed he didn’t know what happened, noting that he consumes alcohol. But he alleged that Zapeta identified himself to interrogators in images related to the attack. Zapeta was taken into custody Sunday afternoon while riding a train on the same subway line after police got a tip from some teenagers who recognized him from images circulated by the police. A Brooklyn address for Zapeta released by police matches a shelter that provides housing and substance abuse support. The shelter did not immediately respond to a request for comment. Federal immigration officials said Zapeta had been previously deported in 2018 but at some point reentered the U.S. illegally. In a statement, Brooklyn District Attorney Eric Gonzalez called the attack a “gruesome and senseless act of violence against a vulnerable woman” that would be “met with the most serious consequences.” The crime — and the graphic video of it that ricocheted across social media — deepened a growing sense of unease among some New Yorkers about the safety of the subway system in a city where many residents take the subway multiple times each day. Overall, according to authorities, crime is down in the transit system this year when compared to last year — major felonies declined 6% between January and November of this year and in 2023, data compiled by the Metropolitan Transportation Authority show. But murders are up, with nine killings this year through November compared to five in the same period last year. Earlier this month, a Manhattan jury acquitted Daniel Penny in the death of an agitated subway rider that the former Marine placed in a chokehold last year. The case became a flashpoint in ongoing debates over safety, homelessness and mental illness on the system. Policing the subway is also difficult, given the vast network of trains constantly moving between the system’s 472 stations, with each stop containing multiple entry points and, in many stations, multiple floors and platforms. On Sunday, police at the station where the woman burned to death were patrolling a different area and responded after seeing and smelling smoke, authorities said. Copyright 2024 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission. Get local news delivered to your inbox!
Cross River: Shelve planned strike – Gov Otu begs labour over minimum wage